Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

French antibiotic maker Eliigo Bioscience gets backing from Seventure Partners, raises 2 million euros in Series A

Seventure Partners, the European venture capital firm has led a 2 million euros Series A round in Paris-based antibiotic maker Eliigo Bioscience. Sebastien Groyer, who is a partner at Seventure will join Eliigo’s board. A spin-off from Massachusetts Institute of Technology and Rockefeller University, Eliigo uses technology to design new ultra precise antibiotics, known as Eligobiotics, which target harmful bacteria, while sparing beneficial ones. The technology is unique and has its first mover advantage over others in the sector, according to representatives at Eliigo. In November, last year, Seventure co-led a 6.3 million euros Series C financing round in Humedics alongside Vesalius Biocapital Partners.


France,Venture/Growth,antibiotics maker,Eligo Bioscience.,Europe,paris,Seventure Partners,venture capital,europe,seventure partners,eligo bioscience.,Eliigo,Massachusetts Institute of Technology ,Rockefeller University,Eligobiotics